ArticleJournal of cancer prevention2026
Differences in Self-purchased Complementary and Alternative Medicine Use and Patient-reported Satisfaction between Female-specific and Non-female-specific Cancer Patients.
Article in Journal of cancer prevention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate demographic and clinical factors associated with use of complementary and alternative medicine (CAM) and to compare CAM utilization patterns, including self-purchase behaviors and patient-reported satisfaction, between Korean women with female-specific and non-female-specific cancers. This exploratory subgroup analysis was conducted among female participants in a cross-sectional survey of Korean adults with solid tumors. Clinical and epidemiological characteristics were compared between CAM users and non-users. CAM use patterns-including reasons for use, initiation timing, duration, cost, self-purchase behavior, patient-reported satisfaction, and adverse effects-were compared between female-specific and non-female-specific cancers. Of the 150 female patients with solid tumors, 93 (62.0%) reported their use of CAM. The prevalence of CAM use was similar between patients with female-specific cancers (64.5%, 69/107) and those with non-female-specific cancers (55.8%, 24/43), with no statistically significant difference observed. However, patients with female-specific cancers were significantly more likely to self-purchase CAM than those with non-female-specific cancers (85.5% vs. 62.5%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.